+1 Recommend
1 collections
      • Record: found
      • Abstract: found
      • Article: found

      Effects of Endogenous Opioid Peptides and Opiates on Luteinizing Hormone and Prolactin Secretion in Ovariectomized Rats



      S. Karger AG

      Luteinizing hormone, Prolactin, Opiates, Opioids, Endorphins, Enkephalins, Opiate receptors

      Read this article at

          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.


          Adult female rats were implanted with permanent cannulae in the third ventricle of the brain and ovariectomized. 3 weeks later, blood samples were withdrawn every 5 min from intraatrial cannulae placed the previous day. After a control sampling period of 30 min, the rats received an intraventricular bolus injection of saline (2 µl) or β-endorphin (βE; 10 µg); sampling was continued for an additional 2 h. Saline injection caused no effect on luteinizing hormone (LH) and prolactin (PRL) secretion. βE stimulated PRL secretion within 5–10 min, the values peaked in the next 10 min. Thereafter, as PRL levels fell, a suppression of LH secretion became apparent. Inhibition of LH release started 20–35 min after βE injection and lasted for 35–65 min. The antecendent PRL secretion was apparently not responsible for the observed delayed LH response, since blockade of PRL response with bromocriptine failed to affect the βE-induced LH suppression. Further, continuous intraventricular infusion of βE (5 or 10 µg/h) for 3 h markedly suppressed the amplitude and frequency of LH episodes in long-term ovariectomized rats. Bolus intraventricular injection of other endogenous opioid peptides and opiate receptor agonists produced different PRL and LH responses. Dynorphin (10 µg) similarly suppressed LH release but was only moderately effective in stimulating PRL. Leucine enkephalin (50 µg) stimulated LH and inhibited PRL release, while methionine-enkephalin (50 µg) selectively stimulated PRL release. The methionine-enkephalin analogs, FK-33824 (50 ng) and DALAMID (50 µg), evoked sequential PRL and LH responses similar to those seen after βE injection. Interestingly, morphiceptin (a specific µ receptor agonist; 10 µg) markedly suppressed LH release, but only sparingly stimulated PRL release. Delta receptor peptide (a specific δ receptor agonist; 10 µg) selectively suppressed LH release. Bremazocine (a specific Kreceptor agonist; 0.5 mg/kg) administered intravenously suppressed LH release selectively. These studies show that (1) of the four endogenous opioid peptides tested βE was most effective in evoking sequential PRL and LH responses, and these effects may be mediated by either Ε receptors or multiple opiate receptor subtypes; (2) stimulation of Kreceptors by bynorphin or bremazocine suppressed LH release, and (3) further studies would be needed to unterstand the mode of action of the two enkephalins and the δ opiate receptors in eliciting disparate PRL and LH responses.

          Related collections

          Author and article information

          S. Karger AG
          28 March 2008
          : 41
          : 4
          : 342-352
          Department of Obstetrics and Gynecology, University of Florida College of Medicine, Gainesville, Fla., USA
          124199 Neuroendocrinology 1985;41:342–352
          © 1985 S. Karger AG, Basel

          Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher. Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug. Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

          Page count
          Pages: 11
          Original Paper


          Comment on this article